BioMarin to acquire Amicus Therapeutics for $4.8bn.

BioMarin, a biotechnology company focused on rare genetic diseases, agreed to acquire Amicus Therapeutics, a biotechnology company, for $4.8bn. "Amicus, like BioMarin, is a company that has been profoundly dedicated to transforming care for patients with rare diseases since its founding, developing and bringing to market important therapies for individuals living with Fabry disease and Pompe disease. BioMarin's scale of operations, including our global commercial footprint and industry-leading, in-house manufacturing capabilities make the combination of these companies an exceptional strategic fit. Immediately upon close, this transaction is expected to accelerate BioMarin's revenue growth and strengthen our financial outlook, delivering significant value to patients, employees and stockholders. The transaction is expected to be accretive to Non-GAAP Diluted EPS in the first 12 months following close," Alexander Hardy, BioMarin President and Chief Executive Officer.